Avandia linked with severe lipid abnormalities

	Tweet

On rare occasions, treatment with rosiglitazone (Avandia) may cause a profound decrease in high-density lipoprotein (HDL, the “good” cholesterol) and an increase in fasting triglycerides, researchers in the UK warn in the journal Diabetes Care.

“This represents a potentially serious adverse event that requires detailed evaluation,” Dr. Anita Sarker and colleagues from Addenbrooke’s Hospital in Cambridge write.

They describe three patients with type 2 diabetes and High cholesterol in whom treatment with rosiglitazone was temporally related to a sharp decline in blood levels of HDL cholesterol.

The patients had a rapid return of HDL cholesterol to pretreatment levels when the drug was stopped.

Despite this abnormal cholesterol response, all three patients experienced “striking improvement” in blood sugar control with rosiglitazone treatment.

Sarker’s team is aware of two other patients with similar responses to rosiglitazone treatment.

The mechanism of rosiglitazone-induced cholesterol abnormalities remains to be determined, they note.

Sarker told Reuters Health: “It is not clear how common this problem is, although, the fact that this phenomenon was not seen in greater than 1400 patients studied in clinical trials suggests that it is likely to be a rare side effect.”

“However, we would suggest that a full lipid profile that includes HDL cholesterol should be measured before starting [rosiglitazone and similar drugs], and rechecked about three months after.”

SOURCE: Diabetes Care, November 2004.

RELATED STORIES:
Treating Gum Disease Linked to Lower Medical Costs for Patients with Diabetes   Skin monitor gives frequent glucose readings   World’s first stem cell bank opens   How poor maternal diet can increase risk of diabetes - new mechanism discovered   Britons at risk of diabetes know little of disease   Many “Pre” Patients May Not be as Healthy as They Think   Diabetics need hours of insulin after pizza   Low vitamin D linked to the metabolic syndrome in elderly people   Pfizer’s Lipitor halves stroke risk in diabetics   Dental Treatment Might Lower Glucose Levels In Type 2 Diabetes   Immune therapy stops diabetes in mouse study   Caffeine interferes with diabetes control

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]